✦ AARP launched a seven-figure, digital ad campaign on July 19 aimed at pressing Congress to support actions to lower drug prices, The Hill reported. The campaign will appear in The New York Times, The Washington Post, CNN, Politico and Axios through July 30 and will focus on the Washington, D.C. area — a move that comes on the heels of the interest group running digital ads on publications’ websites for two weeks ending on June 9. AARP’s ads cite a survey that the group published in June, which found that 87% of people age 50 and older support allowing Medicare to negotiate with drug companies for lower prices and 78% favor putting a cap on out-of-pocket costs for Medicare Part D drugs.
✦ A committee comprising employers, health plans, PBMs, drug manufacturers, health systems, consultants, retailers, wholesalers and other key stakeholders is recommending that the U.S. pharmaceutical supply chain be overhauled to “address long-standing conflicts” and achieve a better delivery model. The committee, convened by the Business Group on Health, met over the past two years to study challenges within the pharmaceutical supply chain, and ultimately issued 70 reform recommendations. One of the key tenets used to guide specific recommendations, for example, is that “benchmarks for drug prices should be established by a transparent and independent third party, informed by a cost-effectiveness analysis and validated by real-world data evaluations.
Unlock the full version of this article by subscribing.